Literature DB >> 10692930

Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration.

O Cekiç1, C Batman, U Yasar, N E Başci, A Bozkurt, S O Kayaalp.   

Abstract

PURPOSE: To assess aqueous and vitreous humour ciprofloxacin concentrations following oral and topical administration of ciprofloxacin in patients with non-inflamed cornea and an intact crystalline lens, and to compare the concentrations of the drug given by either route.
METHODS: In this prospective study, 34 patients undergoing pars plana vitrectomy for various ocular pathologies were divided into two groups. Eighteen patients received 2 drops of 0.3% ophthalmic solution of ciprofloxacin every 30 min for 3 h and then every 60 min for the next 3 h, and 16 patients received a single oral dose of 1000 mg ciprofloxacin 6 h before surgery. The aqueous and vitreous humour samples were simultaneously harvested after oral or topical administration during pars plana vitrectomy to assess penetration of the drug. These samples were assayed for ciprofloxacin concentrations by a method described previously by us using high-performance liquid chromatography.
RESULTS: The aqueous and vitreous humour levels of ciprofloxacin were 0.59 +/- 0.06 microgram/ml (mean +/- SEM) and 0.64 +/- 0.06 microgram/ml after oral and 0.44 +/- 0.07 microgram/ml and 0.22 +/- 0.04 microgram/ml after topical ciprofloxacin administration, respectively. Aqueous humour levels were not statistically significantly different following oral and topical administration (p = 0.069). However, the vitreous level of the drug after oral administration was significantly higher than that after topical administration (p < 0.001).
CONCLUSION: Ocular bioavailability of ciprofloxacin in aqueous humour following oral and topical administration is found to be similar when the drug was applied as described above. Penetration of ciprofloxacin into vitreous humour is less than that into aqueous humour after topical administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10692930     DOI: 10.1038/eye.1999.137

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

1.  Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics.

Authors:  Baozhong Zhao; Colin F Chignell; Mustapha Rammal; Frank Smith; Mary G Hamilton; Usha P Andley; Joan E Roberts
Journal:  Photochem Photobiol       Date:  2010-06-01       Impact factor: 3.421

2.  Salmonella enteritidis bacteremia in at win pair.

Authors:  Devendra Mishra; Vikas Manchanda
Journal:  Indian J Pediatr       Date:  2008-04       Impact factor: 1.967

3.  Sparfloxacin-associated corneal epithelial toxicity.

Authors:  Aniruddha Kishandutt Agarwal; Jagat Ram; Ramandeep Singh
Journal:  BMJ Case Rep       Date:  2014-09-19

4.  Interventions and Outcomes in Patients with Infectious Pseudomonas scleritis: A 10-Year Perspective.

Authors:  Sumayya Ahmad; Michelle Lopez; Marwan Attala; Anat Galor; Natalie A Stanciu; Darlene Miller; Leejee Suh; Thomas Albini; Victor L Perez; Carol L Karp; Janet L Davis; Eduardo Alfonso; Richard K Forster; Guillermo Amescua
Journal:  Ocul Immunol Inflamm       Date:  2017-10-17       Impact factor: 3.070

5.  Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans.

Authors:  O Cekiç; C Batman; U Yaşar; N E Başci; O Zilelioğlu; A Bozkurt
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

6.  Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Authors:  Seenu M Hariprasad; William E Mieler; Gaurav K Shah; Kevin J Blinder; Rajendra S Apte; Nancy M Holekamp; Matthew A Thomas; Jingduan Chi; Randall A Prince
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.